Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Establishment Labs Holdings Inc(ESTA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ESTA
10/23/2026: ESTA (3-star) is currently NOT-A-BUY. Pass it for now.
Establishment Labs is a medical technology company focused on advancing safety and aesthetic outcomes in the breast implant market. The company is known for its Motiva brand, which relies on proprietary surface technologies to differentiate itself from long-standing industry incumbents. While the company has demonstrated strong international growth and maintains a clear innovation pipeline with projects like Motiva Mia, it remains in a high-investment phase with limited profitability. Key risks include intense competition from large-cap players, significant execution risk regarding US regulatory approvals, and sensitivity to elective procedure demand. The stock may suit growth-oriented investors with a high risk tolerance who are looking for exposure to aesthetic medical innovation.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is in an active expansion phase with high revenue growth potential tied to new product and market launches. |
| Momentum investor | Mixed fit | Momentum is highly dependent on regulatory news flow, making it a conditional play on binary catalysts. |
| Value investor | Weak fit | The company is not currently focused on profitability or dividends, which does not align with traditional value metrics. |
| Dividend investor | Weak fit | There is no history of dividends as the company prioritizes capital reinvestment. |
| Low-risk investor | Weak fit | High regulatory risk and volatility make this unsuitable for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to sharp swings based on regulatory updates and clinical trial results. |
| Valuation risk | Medium / high | High growth expectations are often priced into the stock, leaving little margin for error on execution. |
| Competition risk (Breast Implants) | High | Major incumbents with deep pockets and established distribution networks pose a constant threat to market share. |
| Business quality | Medium | While the technology is innovative, the company is still establishing the consistent profitability characteristic of high-quality franchises. |
| Dividend income | Low / none | Investors should expect zero income from this holding. |
| Execution risk | Medium / high | Successfully navigating US regulatory pathways is critical to the company's long-term success. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 60.16% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.90B USD | Price to earnings Ratio - | 1Y Target Price 100.7 |
Price to earnings Ratio - | 1Y Target Price 100.7 | ||
Volume (30-day avg) 378.0K shares | Beta 1.06 | 52 Weeks Range 47.00 - 97.59 | Updated Date 10/23/2026 |
52 Weeks Range 47.00 - 97.59 | Updated Date 10/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.31 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Breast Implants | Sale of silicone gel-filled Motiva breast implants to hospitals, clinics, and plastic surgeons. | The vast majority of revenue comes from selling these high-end medical devices. |
| Geography | Operations spanning international markets including Europe, Asia, and Latin America, with ongoing US market expansion. | International success drives revenue currently, while the US represents the key growth horizon. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 217.39 | Enterprise Value 2.34B | Price to Sales(TTM) 7.73 |
Enterprise Value 2.34B | Price to Sales(TTM) 7.73 | ||
Enterprise Value to Revenue 9.5 | Enterprise Value to EBITDA -26.29 | Shares Outstanding 29.80M | Shares Floating 19.53M |
Shares Outstanding 29.80M | Shares Floating 19.53M | ||
Percent Insiders 10.04 | Percent Institutions 105.48 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.